// STATE LEGISLATION TRACKER

Ohio HB 388 — Regards state employee reimbursement for GLP-1 drug costs

⚖️ MIXED for peptide users 👤 LOW user impact 📜 Status: Unknown

State: Ohio
Bill: HB 388
Filed: 2025-07-01
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

Ohio HB388 appears to address reimbursement of GLP-1 drug costs for state employees. Based only on the title and unavailable status detail, it does not appear to change peptide compounding, telehealth prescribing, clinician scope, FDA 503A/503B rules, controlled substances, or prescription monitoring.

Key Points

May affect GLP-1 cost coverage for Ohio state employees
No clear impact on compounded peptide access from the available title
No telehealth or off-label prescribing change is apparent
No NP or naturopathic scope change is apparent
No controlled-substance or PDMP issue is apparent

What to Watch For

✓

Opportunity If reimbursement expands, eligible state employees may have better access to prescribed GLP-1 drugs.

Note Watch whether the bill covers only FDA-approved GLP-1 products or also addresses compounded versions.

Note Status could not be verified from the provided OpenStates page, so movement in the legislature is unclear.

Where the Bill Stands

The provided source reports that the latest action could not be refetched, so the bill's current legislative stage is unknown.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws